The Cardiovascular Business Forty Under 40 Class of 2026 represents an accomplished group of clinicians, researchers, entrepreneurs and administrators who are redefining what cardiovascular leadership looks like under the age of 40. 

A jury sentenced the former cardiovascular ICU nurse to death for intentionally murdering multiple heart patients. In one TV interview, he said the power associated with the murders became "an addiction" over time. 

With exercise, does timing really matter? According to one new study, working out early in the day was linked to a lower risk of heart disease and healthier blood pressure levels than working out at any other point in the day.

The use of AI technologies in healthcare has evolved at a breathtaking rate in the last few years. Hype and hypotheticals have been replaced with real, practical tools that help physicians focus on providing high-quality care. 

Several U.S. medical societies have collaborated on a new report advocating for better safety standards in cardiac catheterization labs. As one cardiologist described it, clinicians have shifted from "accepting risk" to "expecting better."

Advanced AI software developed by Cleerly consistently produced plaque assessments comparable to intravascular ultrasound. 

The new approach allows private practices to expand and evolve without being acquired.

The OmniaSecure defibrillation lead from Medtronic is already approved for placement in the right ventricle. This latest approval covers the left bundle branch area, opening the door for conduction system pacing and other advanced techniques.

A multidisciplinary research team has found a new use for a reliable medical device. Multiple heart patients have already benefited for the group’s outside-the-box thinking.

Neurosurgeon Vitor Mendes Pereira, MD, was in Santiago, Panama, but his patient was in Panama City. "It is the highlight of my career to be involved in this historic achievement," Pereira said.

The high-risk patients who require urgent or emergent TAVR are often excluded from major clinical trials. To learn more about this population, researchers explored data from nearly 600 patients treated at high-volume facilities.